Dev represents biotech and chemicals clients based in the UK, Europe, and US. He joined the patent profession in the late 1990s at the time of the first biotech boom. Since joining Keltie in 2004 he has developed a thriving international practice specialising in providing strategic advice and support for early stage and rapid growth technology companies particularly in the fields of biological therapeutics, synthetic biology, computational biology & bioinformatics and medical devices. Dev enjoys working closely with clients to help counsel them in devising robust intellectual property strategies through serial funding rounds. He has worked with many clients that have successfully exited by trade sale, or through IPOs on the London Stock Exchange as well as NASDAQ.
His work involves the development of valuable patent positions in competitive global markets, as well as freedom-to-operate and patent landscape analysis. He advises on contentious issues and handles oppositions before the European Patent Office. In 2014 he successfully defended Freedom Innovations' Patent in an opposition referral to the EPO Enlarged Board of Appeal (G3/14).
Dev is a member of the Life Sciences Committee of the Chartered Institute of Patent Attorneys and regularly publishes and presents in the field of biotechnology intellectual property law.
16.06.2022Keltie ranked again one of Europe’s top Patent Law Firms by Financial Times
In a special report based on recommendations from our clients and peers across Europe, the firm was recognised for its exceptional standards of service in all technology sectors, with particularly high accolades in IT, Biotechnology, Materials, Electrical and Mechanical Engineering.
24.08.2020Working with start-ups – interview with Dev Crease.
Dev Crease joined Keltie in 2004 just after he qualified as a UK and European patent attorney. Over past 16 years he has developed a thriving practice in the life sciences, chemical and medical technologies team based around advising rapid growth companies achieve value in their IP positions.
OtherLess related knowledge